Top Page
Pulse Biosciences
(NASDAQ:PLSE)
Pulse Biosciences (PLSE) vs. SPDR S&P 500 ETF (SPY)
Pulse Biosciences Business Overview & Revenue Model
Pulse Biosciences Earnings Call Summary
Pulse Biosciences Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 86.00K | 0.00 | 0.00 | 700.00K | 1.42M | 0.00 |
| Gross Profit | -460.00K | 0.00 | -1.21M | -11.24M | -550.00K | -665.00K |
| EBITDA | -75.77M | -55.08M | -42.37M | -56.70M | -61.87M | -48.87M |
| Net Income | -74.73M | -53.59M | -42.21M | -58.51M | -63.66M | -49.74M |
Balance Sheet | ||||||
| Total Assets | 108.77M | 132.46M | 59.15M | 77.88M | 54.25M | 41.29M |
| Cash, Cash Equivalents and Short-Term Investments | 95.21M | 118.04M | 44.37M | 61.14M | 28.61M | 20.48M |
| Total Debt | 7.89M | 8.90M | 9.14M | 75.96M | 11.25M | 11.36M |
| Total Liabilities | 16.07M | 17.60M | 14.79M | 80.13M | 18.56M | 18.40M |
| Stockholders Equity | 92.69M | 114.86M | 44.36M | -2.25M | 35.69M | 22.89M |
Cash Flow | ||||||
| Free Cash Flow | -48.77M | -36.47M | -33.16M | -47.41M | -54.53M | -35.81M |
| Operating Cash Flow | -48.51M | -36.34M | -33.04M | -47.01M | -54.10M | -35.37M |
| Investing Cash Flow | -283.00K | -125.00K | -121.00K | -401.00K | 7.56M | 10.04M |
| Financing Cash Flow | 64.97M | 110.14M | 16.39M | 79.94M | 62.69M | 30.89M |
Pulse Biosciences Technical Analysis
Pulse Biosciences Risk Analysis
Pulse Biosciences Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $1.72B | -30.63 | 1.41% | ― | -9.49% | 58.97% | |
54 Neutral | $2.28B | -1.97 | -44.21% | ― | -3.43% | 38.98% | |
52 Neutral | $1.20B | -363.17 | -5.20% | ― | -18.82% | 92.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $997.54M | -12.97 | -86.99% | ― | ― | -40.63% | |
46 Neutral | $1.12B | -11.50 | -24.65% | ― | -32.42% | -540.37% | |
42 Neutral | $224.02M | -5.77 | -27.19% | ― | 30.55% | -340.19% |
Pulse Biosciences Corporate Events
On January 8, 2026, Pulse Biosciences elected veteran healthtech executive Maria Sainz to its board of directors and appointed her to the audit committee, with the addition formally announced in a January 9, 2026 press release. Sainz, currently president and CEO of portable MRI maker Hyperfine, brings more than three decades of experience leading public and venture-backed medical device companies through clinical, regulatory, financing and M&A milestones, and will receive standard non-employee director cash retainers, the option to convert retainers into equity, reimbursement of board-related expenses, and time-vested stock option grants that further align her incentives with shareholders. The appointment adds deep commercialization and strategic expertise as Pulse advances its first three nsPFA-based programs through key clinical, regulatory and commercial milestones, underscoring the company’s intention to strengthen governance and bolster its ability to compete and scale in interventional and surgical device markets.
The most recent analyst rating on (PLSE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
On December 18, 2025, Pulse Biosciences announced that the U.S. Food and Drug Administration approved its Investigational Device Exemption, enabling the company to begin the NANOPULSE-AF clinical study of its nPulse Cardiac Catheter Ablation System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The single-arm, multicenter, prospective study will enroll up to 145 patients across as many as 30 sites, including three outside the U.S., to evaluate the safety and effectiveness of the nsPFA-based catheter, which is designed to deliver rapid, circumferential pulmonary vein isolation with lower total energy and potentially reduced collateral injury, building on positive initial results from an ongoing European feasibility study and marking a key milestone in the company’s push to establish its next-generation ablation technology in the global electrophysiology market.
The most recent analyst rating on (PLSE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
On December 9, 2025, Pulse Biosciences, Inc. conducted its 2025 Annual Meeting of Stockholders virtually. During the meeting, stockholders elected six directors to serve until the 2026 meeting, ratified Deloitte & Touche LLP as the independent accounting firm for 2025, approved executive compensation, and decided to hold future advisory votes on executive compensation every three years.
The most recent analyst rating on (PLSE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
On December 9, 2025, Pulse Biosciences announced a research collaboration with The University of Texas MD Anderson Cancer Center to explore the use of its nPulse™ Vybrance™ Percutaneous Electrode System for treating thyroid cancers. The FDA has approved the Investigational Device Exemption for this first-in-human clinical feasibility study, which will begin in early 2026, involving 30 subjects across two sites. This collaboration aims to assess the safety and effectiveness of nPulse technology in treating papillary thyroid microcarcinoma, with ongoing preclinical studies on anaplastic thyroid carcinoma, a particularly deadly cancer. The nonthermal mechanism of nsPFA energy is highlighted for its potential to minimize scarring and damage to surrounding structures, positioning it as a promising treatment for both benign and malignant thyroid tumors.
The most recent analyst rating on (PLSE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
On November 13, 2025, Pulse Biosciences, Inc. released an updated investor presentation on its website, highlighting recent advancements in its product development programs. This presentation is intended for use in discussions with investors and analysts, showcasing the company’s progress with its nPulse technology products, which could influence its market positioning and stakeholder interests.
The most recent analyst rating on (PLSE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
On October 24, 2025, Pulse Biosciences announced the enrollment of the first patient in its NANOCLAMP AF clinical trial, marking a significant milestone for the company’s nPulse™ Cardiac Surgical System. This trial aims to demonstrate the safety and effectiveness of the system in treating atrial fibrillation during concomitant surgical procedures, potentially revolutionizing patient care with improved safety and procedural advantages over conventional methods.
The most recent analyst rating on (PLSE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
On October 10, 2025, Pulse Biosciences announced the results of its first-in-human feasibility study using the nPulse Cardiac Surgical System at the European Association for Cardio-Thoracic Surgery Annual Meeting. The study, which involved 44 patients, demonstrated high success rates in pulmonary vein isolation and posterior box isolation without severe adverse events, indicating the potential for the nPulse system to enhance cardiac surgical ablation for atrial fibrillation.
The most recent analyst rating on (PLSE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.